If you or someone you love takes prescription medications for dementia, diabetes, heart disease, or any chronic condition, there is a strong chance you are paying more than you need to. Pharmaceutical companies, the federal government, and nonprofit organizations all offer programs that provide free or deeply discounted medications to patients who qualify, yet millions of eligible Americans never apply. Consider this: a GoodRx survey found that over 75 percent of patients who used a manufacturer’s patient assistance program said they would have been unlikely to fill their prescription without the financial help. Nearly every major drug company runs one of these programs, and there is no central registry tracking how many people miss out. The gap between what is available and what patients actually use is enormous.
This article walks through the most significant free and reduced-cost medication programs available right now, from manufacturer-sponsored patient assistance to new federal pricing rules that took effect in 2026. Some of these apply specifically to Medicare beneficiaries. Others are open to uninsured and underinsured patients regardless of age. Whether you are managing a parent’s dementia medications, dealing with your own chronic prescriptions, or simply trying to understand what options exist, the programs below could save hundreds or even thousands of dollars a year. We will also cover the practical tools that help you search across all of these programs at once.
Table of Contents
- What Are Patient Assistance Programs and Who Qualifies for Free Medications?
- How Medicare’s New Out-of-Pocket Cap Changes Prescription Costs in 2026
- Which Drugs Now Have Government-Negotiated Prices Under Medicare?
- How to Find the Right Free Medication Program for Your Situation
- The 340B Program and Why Your Hospital Matters
- The $35 Insulin Cap and Mark Cuban’s Cost Plus Drugs
- Free Vaccines and the Outlook for Prescription Affordability
- Conclusion
- Frequently Asked Questions
What Are Patient Assistance Programs and Who Qualifies for Free Medications?
Patient assistance programs, often called PAPs, are run directly by pharmaceutical manufacturers to provide their brand-name drugs at no cost to patients who meet certain income and insurance criteria. Pfizer, Novo Nordisk, Eli Lilly, AstraZeneca, and virtually every other major drugmaker operates one. Pfizer RxPathways, for example, provides free Pfizer medications to uninsured patients and also helps those on government insurance who cannot afford their copays. The program distributes through federally qualified health centers and free clinics, which means patients do not always need to navigate the application alone. Novo Nordisk’s NovoCare program works similarly. Once approved, patients receive their Novo Nordisk medications with no registration charge and no monthly fee. The catch is that you usually have to apply, and the process can feel bureaucratic.
Most PAPs require proof of income, a prescription from your doctor, and documentation showing that you are uninsured or that your insurance does not adequately cover the medication. Income thresholds vary by company, but many programs cover patients earning up to 400 percent of the federal poverty level. Your doctor’s office may have staff who handle these applications regularly, so ask before assuming you need to do everything yourself. Here is the critical limitation: no formal entity tracks total PAP utilization nationally. That means there is no single dashboard or government report telling us how many people could be getting free drugs but are not. The practical result is that awareness depends almost entirely on whether your doctor, pharmacist, or caregiver happens to mention these programs. For families dealing with dementia, where the patient may not be managing their own medications or finances, this is a significant barrier. If you are a caregiver, checking whether the specific medications your loved one takes are covered by a PAP should be one of your first steps.
How Medicare’s New Out-of-Pocket Cap Changes Prescription Costs in 2026
One of the most consequential changes for older adults on prescription medications is the hard annual out-of-pocket cap that went into effect under the Inflation Reduction Act. In 2025, Medicare Part D enrollees hit a ceiling at $2,000 in total out-of-pocket drug spending. For 2026, that cap has been adjusted to $2,100. Once a beneficiary reaches that threshold, they pay nothing for covered prescriptions for the rest of the calendar year. An estimated 11 million Part D enrollees are expected to hit the cap, saving an average of roughly $600 per person per year. This matters enormously for dementia patients, who often take multiple medications simultaneously, including cholinesterase inhibitors, memantine, and drugs for co-occurring conditions like hypertension or diabetes. Before this cap existed, patients in the old Part D “donut hole” coverage gap faced punishing costs precisely when their annual spending was highest.
That coverage gap has been eliminated entirely as of 2025. The progression is now straightforward: you pay your deductible, then your copays or coinsurance, and once your out-of-pocket total reaches $2,100 in 2026, your cost-sharing drops to zero for the remainder of the year. However, this cap applies only to Part D drug costs. It does not cover Part B medications administered in a clinical setting, and it does not help patients who are uninsured or on commercial insurance plans. If your loved one with dementia receives infused medications at a clinic, those costs fall under a different structure. Also, the cap resets every January, so a patient with consistently high drug costs will reach the threshold each year rather than enjoying a permanent reduction. Still, for the millions of seniors who previously faced open-ended prescription expenses, this is a genuine financial floor that did not exist before.
Which Drugs Now Have Government-Negotiated Prices Under Medicare?
For the first time in the program‘s history, Medicare has negotiated prices directly with pharmaceutical manufacturers, and those negotiated prices took effect in 2026. The initial round covers ten high-cost drugs. Eliquis, used widely for blood clot prevention, dropped from $521 per month to $231, a 56 percent reduction. Jardiance, a diabetes medication, fell from a $573 list price to $197 per month, a 66 percent cut. The full list also includes Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog. The estimated impact is significant. Medicare beneficiaries are projected to save $1.5 billion in out-of-pocket costs, while the Medicare program itself saves roughly $6 billion per year.
Across stand-alone Part D plans, average cost-sharing for these ten drugs has decreased by approximately 50 percent. For patients on fixed incomes juggling multiple prescriptions, that kind of reduction can be the difference between filling a prescription and skipping it. A real-world example: a Medicare beneficiary taking both Eliquis and Jardiance was previously looking at combined monthly costs that could easily exceed $1,000 at list price, before insurance. Under the negotiated prices, those same two drugs now cost $428 per month combined before plan coverage kicks in. These savings flow through to copays and coinsurance, meaning the patient’s actual share drops substantially. The limitation here is that only ten drugs are included so far. If your medication is not on the list, you will not see negotiated pricing until future rounds expand the program. Additional drugs are expected to be added in subsequent years, but the timeline and selection process remain subject to political and legal challenges.
How to Find the Right Free Medication Program for Your Situation
With so many programs available, the practical challenge is figuring out which ones apply to your specific medications and financial circumstances. Several free search tools exist precisely for this purpose. NeedyMeds, a nonprofit at needymeds.org, maintains a clearinghouse of patient assistance programs, drug coupons, and rebates. It is entirely free to use and even offers its own discount card. RxAssist at rxassist.org bills itself as the most comprehensive web directory of patient assistance programs and is a strong starting point for research. The PhRMA Medicine Assistance Tool at medicineassistancetool.org lets you search specifically for industry-sponsored assistance programs by drug name. GoodRx operates differently. Rather than connecting patients with free medications, it aggregates pricing across pharmacies and offers discount coupons that can reduce the cash price of prescriptions. The average GoodRx user saves $276 per year, and approximately one in three U.S. physicians have recommended it to patients.
The tradeoff with GoodRx is that you are comparing discounted prices rather than accessing truly free medication. For someone who does not qualify for a PAP due to income limits but still finds their prescriptions unaffordable, GoodRx can bridge the gap. For someone who does qualify for a PAP, the manufacturer program will almost always be the better deal because the medication is free. A newer option is the TrumpRx.gov platform, launched on February 5, 2026. This federal website aggregates direct-to-consumer drug discounts for uninsured, Medicaid, and cash-paying patients. Launch partners include AstraZeneca, offering up to 80 percent off chronic disease drugs, and Eli Lilly, providing GLP-1 medications at roughly 50 percent off list price through LillyDirect. Pfizer, Novo Nordisk, and EMD Serono are also participating. The platform is based on most-favored-nation pricing agreements with manufacturers. It is still early, and the long-term scope of the program will depend on how many manufacturers join and whether the discounts prove durable. But for patients who are currently paying full price out of pocket, it is worth checking.
The 340B Program and Why Your Hospital Matters
The 340B Drug Pricing Program is one of the least understood but most impactful programs in American healthcare. It requires pharmaceutical companies to sell outpatient drugs at 25 to 50 percent discounts to qualifying hospitals and clinics that serve low-income and uninsured patients. In 2022 alone, 340B hospitals provided nearly $100 billion in community benefits, a 47 percent increase from 2019. Those savings fund free care for uninsured patients, free vaccine programs, mental health clinics, and community health initiatives. The important nuance is that the benefit often flows through the institution rather than directly to the patient. If you receive care at a 340B-eligible hospital or federally qualified health center, the facility is purchasing your drugs at a steep discount, and that savings may be passed on to you through reduced charges, sliding-scale fees, or charity care programs.
But if you fill your prescriptions at a retail pharmacy unconnected to a 340B entity, you will not see these discounts. Where you get your care matters, and not all hospitals or clinics participate. There is also regulatory uncertainty. In February 2026, a federal court vacated a new 340B Rebate Model Pilot Program, and the Department of Health and Human Services is currently reconsidering its implementation. For patients, this means the program continues to operate under existing rules, but future changes could alter how discounts are structured or which entities qualify. If you are receiving care at a community health center or safety-net hospital, ask specifically whether they participate in 340B and what that means for your prescription costs.
The $35 Insulin Cap and Mark Cuban’s Cost Plus Drugs
Two other programs deserve specific mention for their impact on medication affordability. Medicare beneficiaries now pay no more than $35 per month per covered insulin product under both Part B and Part D. In 2026, the cap could actually fall below $35 if 25 percent of the negotiated price comes in lower. This is meaningful for the many dementia patients who also manage diabetes. However, the $35 cap applies only to Medicare. It does not cover patients on commercial insurance or those who are uninsured.
That provision was stripped from the Inflation Reduction Act during negotiations. Some manufacturers, including Eli Lilly, have voluntarily capped their insulin at $35 for non-Medicare patients through their own programs, but this is voluntary and not guaranteed to continue. Mark Cuban’s Cost Plus Drugs takes a different approach entirely. The company’s pricing model is transparent: manufacturer cost plus a 15 percent markup, plus a $5 pharmacy fee, plus $5.25 for shipping. Giant Eagle pharmacies now accept the Team Cuban Card for in-store discounts, and the company has partnered with 9amHealth to offer affordable GLP-1 medications through employer plans. Cost Plus Drugs is also pushing the FDA for generic drug fee waivers to expand into high-cost and shortage medications. This model works best for patients paying cash for generics, where the price transparency can yield dramatic savings compared to retail pharmacy pricing.
Free Vaccines and the Outlook for Prescription Affordability
One easily overlooked provision of the Inflation Reduction Act is that all recommended adult vaccines are now free under Medicare Part D. Previously, only some vaccines were covered without cost-sharing, leaving beneficiaries to pay out of pocket for others, including the shingles vaccine, which can cost over $200. For older adults and dementia patients who may be at elevated risk for complications from preventable illnesses, removing the cost barrier for vaccines is a straightforward public health win. Looking ahead, the trajectory is toward broader drug price negotiation, more manufacturer participation in discount platforms, and continued expansion of the $2,100 out-of-pocket cap model. But none of these changes help if patients and caregivers do not know the programs exist.
The single most important step anyone managing chronic medications can take is to check eligibility for every program described in this article. Start with the free search tools, ask your doctor’s office about PAPs for specific brand-name drugs, and confirm whether your pharmacy or clinic participates in 340B. The programs are there. The savings are real. The only missing piece, more often than not, is awareness.
Conclusion
The landscape of free and discounted medication programs is broader than most patients and caregivers realize. Between manufacturer patient assistance programs, Medicare’s new $2,100 out-of-pocket cap, government-negotiated drug prices, the 340B program, insulin caps, Cost Plus Drugs, TrumpRx.gov, and free search tools like NeedyMeds and RxAssist, there are multiple pathways to reducing or eliminating prescription costs. For families managing dementia alongside other chronic conditions, these programs can free up hundreds or thousands of dollars annually, money that can go toward caregiving, home modifications, or simply reducing financial stress during an already difficult time. The common thread across all of these programs is that none of them are automatic.
Every one requires the patient or caregiver to take a step, whether that means filling out an application, switching pharmacies, checking a website, or having a conversation with a doctor. If you take away one thing from this article, let it be this: ask. Ask your doctor, ask your pharmacist, ask the hospital billing department. The worst answer you can get is that you do not qualify, and the best answer might be that your medications are free.
Frequently Asked Questions
Do patient assistance programs cover dementia medications like donepezil or memantine?
It depends on the manufacturer. Brand-name dementia drugs may be covered by the company’s PAP, but generic versions, which now include donepezil and memantine, are typically too inexpensive to be included in assistance programs. Check NeedyMeds or RxAssist by drug name to see what is available for your specific prescription.
Can I use more than one discount program at the same time?
Generally, you cannot stack manufacturer coupons with Medicare or Medicaid benefits, as this violates federal anti-kickback rules. However, you can use GoodRx or Cost Plus Drugs if you are paying cash, and you can apply for a PAP separately if you are uninsured. The key is to check the terms of each program, because combining certain benefits is illegal while using them independently is fine.
Does the Medicare $2,100 out-of-pocket cap apply to medications administered in a doctor’s office?
No. The cap applies to Part D prescription drugs that you fill at a pharmacy. Medications administered in a clinical setting, such as infusions, typically fall under Part B, which has a separate cost-sharing structure. This distinction matters for some dementia treatments and many cancer drugs.
Is the $35 insulin cap available to people without Medicare?
Not as a federal requirement. The Inflation Reduction Act’s $35 cap is limited to Medicare beneficiaries. However, some manufacturers like Eli Lilly have voluntarily capped insulin prices at $35 for non-Medicare patients through their own programs. Check with your insulin manufacturer directly or search on TrumpRx.gov for available discounts.
What is the income limit for patient assistance programs?
It varies by manufacturer, but many PAPs cover individuals earning up to 400 percent of the federal poverty level, which for a single person in 2026 is roughly $62,000 per year. Some programs have higher or lower thresholds. The only way to know for certain is to check the specific program for your medication.
